Author:
V.A. KUTASHOV, O.V. ULYANOVA
FSBEI in Voronezh State Medical University named after N.N. Burdenko »Ministry of Health of Russia, Voronezh, Russia
Author:
V.A. KUTASHOV, O.V. ULYANOVA
FSBEI in Voronezh State Medical University named after N.N. Burdenko »Ministry of Health of Russia, Voronezh, Russia
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2019, Vol. 119, No. 12, Issue 2
Abstract:
Objective of the study. To study the efficacy and safety of Mexidol therapy administered intravenously by drip (500 mg once daily) for 14 days, followed by oral administration of Mexidol Forte 250, 250 mg 3 times daily for 60 days in patients with chronic cerebral ischemia (CCI). Material and methods. The study included 56 patients with CCI that developed against the background of a combination of arterial hypertension and atherosclerosis. The results of physical examination methods (blood pressure, heart rate, etc.), the dynamics of complaints, indicators on the Clinical Global Impression (CGI), MoCa, asthenia MFI 20, anxiety and depression scales of Hamilton, Tinnetti. Results and conclusion. The study results demonstrated the efficacy and safety of intravenous Mexidol followed by oral Mexidol Forte 250. This treatment regimen resulted in a regression of objective and subjective symptoms of chronic cerebral ischemia and improvements in emotional, cognitive, and motor functioning. Key words: chronic cerebral ischemia, atherosclerosis, arterial hypertension, movement disorders, cognitive impairment, Mexidol, Mexidol Forte 250.
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com